Kornimate/medical-research-clean huggingface dataset:
joovvin' for your skin health study

Conditions: Skin Inflammation; Acne; Skin Diseases; Dermatological Non-Disease; Skin Condition; Eczema

Summary: sixty day single arm trial examining self-report and remote dermatology assessment of cosmetic skin health after daily 10-20 minute sessions with an infrared light therapy device (the joovv mini)


Eligibility criteria:
inclusion criteria: * willingness to use device for 60 days * willingness to place security deposit on device of $149.99 * us resident with an address than can accept ups deliveries * 18 years old * no serious medical conditions * no medically treatable skin diseases * willingness to take a selfie with mobile phone exclusion criteria: * retinoid use * prior use of light therapy within the past 6 months * pregnant or nursing * dietary supplements for skin, hair or nail health
local anesthesia in molar teeth with molar incisor hypomineralization

Conditions: Molar Incisor Hypomineralization

Summary: to compare responses to electrical pulp test (ept) and cold test among molar incisor hypomineralization (mih)-effected and not mih-effected carious teeth before and after administration of local anesthesia for caries removal.

fifty carious permanent first molar teeth (25 mih-effected, 25 not mih-effected) were included. firstly, radiographic caries depth, international caries detection and assessment system (icdas) codes and mih levels of teeth were recorded. then, during the treatment, ept and cold test were performed before and after the administration of local anesthesia. visual analog scale for pain was used to evaluate cold test and pain during treatment. when interpreting results, significancy level was stated for the values of p\<0.05.

Eligibility criteria:
inclusion criteria: * healthy participants exclusion criteria: * not being cooperative during treatment procedure

Keywords: anesthesia cold test electrical pulp test
rituximab therapy for steroid-refractory chronic graft versus host disease

Conditions: Graft vs Host Disease

Summary: the purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (gvhd).

patients will receive rituximab intravenously one time per week for four consecutive weeks. once therapy is completed, the patient will have weekly visits with their physician for four more weeks, at which they will complete a simple questionnaire designed to evaluate the severity of chronic graft versus host disease. at the end of the eighth week on the study (4 weeks of study treatment and 4 weeks of observation), patients will be evaluated to determine whether their chronic graft versus host disease (gvhd) has resolved. if chronic graft versus host disease has resolved entirely, the patient will be monitored for the remainder of the year. if after the initial eight weeks on the study the patient still has symptoms or signs of gvhd, they may receive a second four week study treatment. if the patients' chronic gvhd reappears after receiving either one or two courses of rituximab, a third and final four week course of medication can be given provided it has been at least eight weeks since the last dose. blood tests will be performed at the beginning of the study, after 8 weeks on the study, after 16 weeks on the study and at the end of 1 year.

Eligibility criteria:
inclusion criteria: * recipients of matched related, matched unrelated, or mismatched stem cell transplantation * at least 180 days since allogeneic stem cell transplantation procedure * patients must have steroid-refractory chronic gvhd, defined as having persistent signs and symptoms despite the use of prednisone * stable dose of corticosteroids for 4 weeks prior to enrollment * adequate bone marrow function: absolute neutrophil count (anc) \> 500/mm; platelets \> 20,000 ul * adequate renal function: creatinine \< 3.0 mg/dl * adequate hepatic function: bilirubin \< 3.0 mg/dl; ast \< 90 iu exclusion criteria: * prednisone requirement greater than 2 mg/kg/day or equivalent * known life-threatening sensitivity to rituximab or other anti-b cell antibody. * prior exposure to any new immunosuppressive medication in the preceding 4 weeks prior to enrollment. * active, uncontrolled infection * evidence of natural exposure to hepatitis b or c. * active malignant disease relapse * donor lymphocyte infusion within the preceding 100 days. * life expectancy of less than 3 months. * pregnancy or lactation * evidence of hiv seropositivity

Keywords: steroid-refractory chronic graft vs. host disease chronic graft vs. host disease gvhd steroid-refractory rituximab
metabolic side-effects for second-generation antipsychotics

Conditions: Mental Disorders

Summary: second-generation antipsychotics (sgas), including clozapine, are commonly used nowadays as treatment for psychosis. there are increasing concerns about their related metabolic side-effects over weight gain, risks to cause glucose intolerance and hyperlipidemia, and a specific condition known as metabolic syndrome. all these side-effects might be associated with the increased risk of cardiovascular diseases and diabetes mellitus. this study is to analyze the simple physical measurements (weight and height) and venous blood tests (for fasting blood glucose and lipid) results collected routinely since 2008 (recommended by the local hospital authority as a territory-wide "sgas monitoring program") from those outpatients receiving sgas (amisulpride, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone) and/or clozapine, at a local psychiatric outpatient clinic in hong kong. the investigators hypothesized that there should be differential risks on metabolic side-effects amongst these sgas.


Eligibility criteria:
inclusion criteria: * was ≥18 years of age * out-patients * had received any one of these antipsychotics: aripiprazole, amisulpride, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone * consented to provide physical measurements and venous blood samples exclusion criteria: * not consented to provide venous blood samples and/or physical measurement

Keywords: metabolic sgas clozapine
erlotinib intercalated with chemotherapy versus erlotinib as first line treatment in stage iiib/iv nsclc patients with egfr mutation

Conditions: Non-Small Cell Lung Cancer

Summary: this 2 arm study will compare the efficacy and safety of treatment with erlotinib intercalated with platinum-based therapy or erlotinib along, as first line treatment in stage iiib/iv non-small cell lung cancer patients with epidermal growth factor receptor (egfr) mutation. patients will be randomized to receive gemcitabine (1000mg/m2 iv) on days 1 , and cisplatin (75mg/m2) or carboplatin (5xauc)on day 1, followed by erlotinib 150mg/day from day 15 to day 28 of each 4 week cycle for a total of 6 cycles,then followed by erlotinib monotherapy, or erlotinib 150mg/day .the anticipated time on study treatment is until disease progression, and the target sample size is 60 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age;advanced (stage iiib/iv)non-small cell lung cancer;measurable disease;ecog performance status 0-2. exclusion criteria: * prior exposure to agents directed at the her axis;prior chemotherapy or systemic anti-tumor therapy after advanced disease;unstable systemic disease; any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix.

Keywords: nsclc egfr-tki
study of ati-1777 in patients 12 to 65 years old with mild to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a phase 2b study to determine the safety, tolerability, pharmacokinetic (pk), and efficacy of ati-1777 in patients 12 to 65 years old with mild to severe atopic dermatitis. eligible participants will apply either ati-1777 or vehicle topical solution once daily or twice daily for 4 weeks.


Eligibility criteria:
inclusion criteria: 1. able to comprehend and willing to sign the irb approved icf/assent prior to administration of study-related procedures. 2. male patients or non-pregnant, non-nursing female patients 12 to 65 years old, inclusive, at the time of informed consent/assent. 3. have at least a 6-month history of ad prior to the screening visit, and no significant ad flares for the 4 weeks prior to the screening visit. exclusion criteria: 1. unstable course of ad (spontaneously improving or rapidly deteriorating) based on the patient history or as determined by the investigator during the screening period. 2. concomitant skin disease or clinically infected ad or presence of other skin disease in the area to be dosed that may interfere with study assessments. 3. female patients who are pregnant, nursing, or planning to become pregnant during the study.
liposomal bupivacaine at cesarean delivery to decrease post-operative pain

Conditions: Pain, Postoperative

Summary: this is a randomized controlled trial to test whether the use of liposomal bupivacaine at the time of cesarean delivery may decrease post-operative pain scores.

this study is a randomized controlled trial. a total of 80 patients will be randomized 1:1 to intervention (liposomal bupivacaine) versus control (placebo solution). the planned intervention is the infiltration of liposomal bupivacaine (or control) at the time of fascial closure at a pfannenstiel incision, after the delivery of the infant and repair of the hysterotomy. the procedure to instill the drug is as follows: once the patient is in the operating room, neuraxial anesthesia will be administered per routine practice. a pfannenstiel skin incision will be made. the usual cesarean delivery procedure will be performed at the discretion of the surgeon. once the surgical team is about to begin fascial closure, the study drug will then be infiltrated by a member of the study team, with 50% of the study solution in subcutaneous space and 50% in the fascial plane, taking care to evenly spread the drug in the superior and inferior aspects of the incision. for the fascial infiltration, liposomal bupivacaine will be preferentially infiltrated laterally. the remainder of the cesarean delivery will proceed according to the usual fashion. at any point in the cesarean delivery, the surgeon may chose to administer or withhold ketorolac. post-operative pain management will be: intrathecal morphine, scheduled ketorolac 30mg iv x 24h followed by ibuprofen 600mg q6h x 24h, scheduled tylenol 650mg q6h x 48h, and prn oxycodone 5-10mg q4h. this is the current pain management protocol for postoperative women after cesarean delivery. if tylenol or nsaids are contraindicated, either due to the discretion of the clinical team or pre-existing patient contraindication, these will not be administered but are not a reason for study exclusion. the investigators plan to enroll 80 patients into this pilot study, 40 per group. this sample size is based on prior data among women who had a cesarean delivery at this institution, and were asked to report their pain scores with activity at 48- and 72- hours after operation. with this sample size, the investigators have 80% power to detect a 1.5 point difference in pain at 48 hours, and 90% power to detect a 1.5 point difference in pain at 72 hours, and account for any protocol violations or loss to follow-up.

Eligibility criteria:
inclusion criteria: 1. scheduled cesarean delivery via pfannenstiel incision; 2. planned neuraxial anesthetic with intrathecal morphine and fentanyl administration. exclusion criteria: 1. current or prior use of methadone, buprenorphine, or other opioids before cesarean delivery; 2. contraindication to neuraxial anesthetic; 3. allergy to local anesthetic; 4. planned general anesthetic.
proteomics of severe traumatic brain injury: a feasibility study

Conditions: Brain Injuries, Traumatic

Summary: the purpose of this study is to: 1. determine the temporal course of matrix metalloproteinase (mmp) expression in patients wiht severe traumatic brain injury 2. determine the temporal course of the expression of mmp-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury 3. describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to mmp and neuroinflammatory marker concentrations.


Eligibility criteria:
inclusion criteria: * patient is 18 years of age or older * patient has gcs less than 9 * patient requires intracranial pressure monitoring * patient life expectancy greater than 72 hours exclusion criteria: * patient's tbi is greater than 24 hours old * patient is less than 18 years of age * patient does not require intracranial pressure monitoring * patient has life expectancy less than 72 hours * patient has gcs greater or equal to 9 * patient is currently enrolled in another study

Keywords: craniocerebral trauma matrix metalloproteinase microdialysis
sexual health of women with genital mutilation seen at the saint-denis women's center

Conditions: Female Genital Mutilation; Sexual Dysfunctions, Psychological; Sexual Health; Violence Against Women; Post-Traumatic Stress Disorders; Acculturation; Women&#39;s Health Services; Refugees

Summary: this study looks at the sexual health of women who have experienced female genital mutilation (fgm) and who are receiving care at the women's center at saint-denis hospital. it aims to better understand their sexual experiences, including the impact of past violence and trauma, and to explore how multidisciplinary care (such as psychological and sexological support) can help. the study also looks at what women expect from their care and how they feel about surgical or other types of support.


Eligibility criteria:
inclusion criteria: * women with female genital mutilation (fgm), or considered to be excised, consulting at the maison des femmes (women's house) at saint-denis hospital. * women enrolled in the multidisciplinary care pathway for fgm. exclusion criteria: - women under the age of 15.
a post-marketing observational database study monitoring the safety of cecolinⓡ

Conditions: Autoimmune Diseases; Adverse Pregnancy Outcomes

Summary: this study was a retrospective-prospective real-world study to assess the safety among females receiving the 2vhpv vaccine (cecolinⓡ).

this study was initiated following the approval of the recombinant human papillomavirus bivalent (types 16, 18) vaccine (escherichia coli) (cecolinⓡ) in china. we undertook a retrospective-prospective real-world study to assess the incidence of new-onset autoimmune conditions (10 conditions in rheumatologic/hematologic, gastroenterologic, endocrinologic, and ophthalmologic) and adverse pregnancy conditions (e.g., premature birth, birth defects) among 9-45 yoa females during the pre- and post-marketing period of cecolinⓡ.

Eligibility criteria:
inclusion criteria: * females aged 9 to 45 years registered at the xiamen health and medical big data center; * having at least two records in the xiamen health and medical big data center with an interval of 12 months or more. exclusion criteria: -
feasibility and safety study of parent-to-child nasal microbiota transplant

Conditions: Staphylococcus Aureus; Microbial Colonization; Neonatal Infection

Summary: this feasibility and safety pilot study looks to determine whether transferring a parents healthy, diverse nasal microbiota to the participant's infant(s) will create a healthy, diverse neonatal nasal microbiome.

the parent-to-child nmt study is a pilot study to test the feasibility of a parent-to-child nasal microbiome transplant. the investigators will test parent-to-neonate nasal microbiome transplantation as an intervention to reduce s. aureus acquisition in neonates. neonates admitted to the johns hopkins hospital neonatal intensive care unit (nicu) will be screened and parents will be approached for enrollment in the study. after consent and baseline screening of parents and neonates, eligible neonates will undergo a nasal microbiome transplant. this pilot study looks to determine whether transferring a parents healthy, diverse nasal microbiota to the infant(s) will create a healthy, diverse neonatal nasal microbiome. the investigators are planning an upcoming randomized controlled trial of this intervention and hope to establish feasibility during this pilot study.

Eligibility criteria:
inclusion criteria: neonate: 1. neonate has anticipated nicu length of stay \> 7 days 2. neonate ≥25 weeks gestation 3. at least one parent/adult provider not colonized with s. aureus (as determined by baseline screening) 4. neonate is not colonized with s. aureus on baseline screening parent/adult provider: 1. parent/adult provider is able to provide informed consent. exclusion criteria: neonate: 1. neonate has had a prior clinical or surveillance culture grow s. aureus 2. neonate is a ward of the state 3. neonate with antenatal suspicion for immunodeficiency (e.g. sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency) 4. neonate cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing) parent/adult provider: 1. parent/adult provider had positive covid-19 test in prior 21 days 2. parent/adult provider with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough) 3. parent/adult provider has been in close contact with someone in the last 7 days who had a respiratory viral infection, like the cold or the flu? 4. parent/adult provider tests positive on baseline screening test for s. aureus nasal colonization. 5. parent/adult provider tests positive on baseline screening test for a respiratory pathogen. 6. parent/adult provider is not able to provide written informed consent 7. parent/adult provider is not able to be present at the bedside at the time of intervention. 8. parent/adult provider has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism. 9. inability or unwillingness to complete the donor questionnaire or a positive response to any question on the donor questionnaire

Keywords: microbiome
dyspareunia in women with endometriosis: impact of surgery on sexual health

Conditions: Dyspareunia; Endometriosis

Summary: endometriosis is a disease that affects different areas of individual functioning, including the area of sexual life. women with endometriosis have an impairment of desire and sexual arousal, orgasmic capacity reducted because of the pain and deep dyspareunia. the aim of the study is to evaluate the effectiveness of surgery on dyspareunia in women with endometriosis, taking into account other variables involved in determining dyspareunia: the quality of the couple relationship, anxiety and depression, body image, coping strategies and resilience.


Eligibility criteria:
inclusion criteria: * women affected by endometriosis with dyspareunia; * women in waiting list for surgery exclusion criteria: * severe underlying comorbidities (gynecological, cardiovascular, respiratory, renal, hematological, endocrine, hepatic, gastrointestinal, neurological) * psychiatric diseases * refusal or inability to sign the informed consent * pregnancy * previous gynecological surgery * end of couple relationship
can a vocal stimulus provoke spontaneous breathing in an ischemic stroke patient dependent on mechanical ventilation?

Conditions: Patients Ventilated by Mechanical Ventilation With Ischemic Stroke

Summary: vocal stimulation may encourage spontaneous breathing in patients dependent on mechanical ventilation. the study will include 30 patients on mechanical ventilation that will be intervened by the vocal stimulation and 30 patients on mechanical ventilation will serve as the control group.

vocal stimulation may encourage breathing in ventilated patients dependent on mechanical ventilation. the study will include 30 patients on mechanical ventilation that will be intervened by the vocal stimulation and 30 patients on mechanical ventilation that will be our control group.

Eligibility criteria:
inclusion criteria: * ischemic stroke men and women older than 18 years old and younger than 80 years old exclusion criteria: * coma from other reasons other than ischemic stroke hemmorhagic stroke active malignancy renal failure

Keywords: mechanical ventilation ischemic stroke
an exploration of the impact of pain education on gp practice staff

Conditions: Chronic Pain

Summary: the aim of the research project is to quantify gp practice staffs' knowledge of chronic pain, their attitudes towards people with chronic pain and their management of a hypothetical patient with chronic pain, following a pain education session. the study also seeks to explore gp practice staffs' experience of receiving the pain education, their understanding of pain following the education and if they perceive the education session has impacted upon their daily practice.

inappropriate, biomedical based views of chronic pain are commonly held by health care professionals (hcps) and these in turn can result in patients receiving sub-optimal care out of step with current guidelines. it has been found that healthcare professionals management techniques did not reflect recognised treatment guidelines and this was associated with their biomedical view of chronic pain. pain education/training sessions for health care staff may be an important step towards improving patient care for chronic pain. it has been found that there was improvement in nurses' knowledge after 2 different pain education sessions delivered to nurses however there was no long term follow up. furthermore, no studies have targeted all members of staff at a gp surgery who will interact with the patient, and thus impact upon the care they receive. pain neuroscience education (pne) is an approach to pain education which uses pain science information to shift the belief system of the receiver away from a biomedical understanding of pain to a more biopsychosocial understanding of pain. a number of studies have shown that this education can decrease biomedical attitudes in health care students. thus, it may be that this education could produce similar positive effects in gp practice staff that could have positive implications for the care of patients with chronic pain. thus this study aims to assess the impact on attitudes and beliefs of pain education upon staff at a gp surgery in middlesbrough. attitudes and beliefs will be assessed before and after the delivery of education. in addition participants will be invited to attend one of two focus groups to further discuss their findings or thoughts about the lecture.

Eligibility criteria:
inclusion criteria * clinical non-nhs staff at a middlesbrough gp surgery. exclusion criteria * non-clinical staff at a middlesbrough gp surgery and staff who are not directly employed by the surgery.

Keywords: chronic pain staff attitudes and beliefs education gp surgery